Stendhal grows its portfolio of cancer therapies through an alliance with Adienne.
With the innovative delivery system TEPADINA®, cancer patients will be able to be treated outside health centers in the future.

Stendhal announces a strategic partnership with Nutricia to market nutritional solutions in Mexico.

Stendhal was recognized within the Top 15 in the ranking of the Most Ethical Companies in Mexico.

Due to the pandemic, Mexicans will have faster access to innovative therapies.

Stendhal and Alnylam announce a strategic alliance to offer RNAi therapies in Mexico, Costa Rica, Guatemala, Panama, and the Dominican Republic.

The pharmaceutical company Stendhal and its general director Rodrigo Ruiz received the insignia of "Empresa de Diez" (Company Excellency) granted by INFONAVIT.

Rodrigo Ruiz Mingramm, COO of Stendhal, will continue as President of the AMIIF for a second period.

In order to support the well-being and health of Mexicans, Stendhal shares the different symptoms to detect high blood pressure in time and provide effective therapy at the right time.

Migraine is a neurovascular disorder that affects more than one billion people worldwide, making it the second leading cause of disability in people under the age of 50.

Stendhal helps you spot the signs that your child may have epilepsy.

January 18 is the saddest day of the year; identify whether it is temporary or it could be depression.

Stendhal strengthens its portfolio of rare disease therapies in partnership with North American laboratory BioMarin.

Stendhal offers Agomelatine, an effective and unique molecule that helps in the treatment of moderate to severe depression.

Stendhal offers the Mexican population a treatment to reduce and control cardiovascular risk.